Phase II Study of Docetaxel and Gefitinib as Second-Line Therapy in Gemcitabine Pretreated Patients with Advanced Pancreatic Cancer

被引：33
|
作者：
Brell, Joanna M. [1 ]
Matin, Khalid [2 ]
Evans, Terry [2 ]
Volkin, Robert L. [2 ]
Kiefer, Gauri J. [2 ]
Schlesselman, James J. [2 ]
Dranko, Shelley [2 ]
Rath, Linda [1 ]
Schmotzer, Amy [2 ]
Lenzner, Diana [2 ]
Ramanathan, Ramesh K. [2 ]
机构：
[1] Univ Hosp Case Med Ctr, Ireland Canc Ctr, Cleveland, OH USA
[2] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA
来源：
ONCOLOGY | 2009年 / 76卷 / 04期
关键词：
Docetaxel; Gefitinib; Pancreatic cancer; Phase II; second-line therapy; GROWTH-FACTOR-RECEPTOR; SOUTHWEST-ONCOLOGY-GROUP; CELL LUNG-CANCER; CHEMOTHERAPY; TRIAL; OXALIPLATIN; 5-FLUOROURACIL; IRINOTECAN; CARCINOMA; ERLOTINIB;
D O I：
10.1159/000206141
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background: There is no standard second-line therapy for advanced pancreatic cancer (APC). We evaluated the epidermal growth factor receptor (EGFR) inhibitor gefitinib and docetaxel in a phase II study following gemcitabine failure. Methods: EGFR overexpression was not required. The initial docetaxel dose was 75 mg/m(2) on day 1 every 21 days. Due to febrile neutropenia in 8 of the first 18 patients, the dose was reduced to 60 mg/m(2). Gefitinib, 250 mg/day orally, was given continuously. Results: Forty-one patients received treatment and were evaluable. Febrile neutropenia was seen in 11 patients (27%), with most events occurring at the docetaxel dose of 75 mg/m(2) (8 of 18 patients). Common treatment-related grade 3/4 toxicities were: fatigue (7%), nausea (7%), diarrhea (5%) and vomiting (2%). There was 1 partial response and stable disease in 19 patients. Time to progression was 1.8 months and median survival was 4.5 months (95% CI 2.9-5.7). Conclusion: The tolerability and feasibility of second-line therapy for APC was demonstrated. The combination of gefitinib and docetaxel showed evidence of limited efficacy. Copyright (C) 2009 S. Karger AG, Basel
引用
下载
收藏
页码：270 / 274
页数：5
相关论文
共 50 条
  • [21] Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer:: a multicenter phase II trial
    Boeck, S.
    Weigang-Koehler, K.
    Fuchs, M.
    Kettner, E.
    Quietzsch, D.
    Trojan, J.
    Stoetzer, O.
    Zeuzem, S.
    Lordick, F.
    Koehne, C. -H.
    Kroening, H.
    Steinmetz, T.
    Depenbrock, H.
    Heinemann, V.
    ANNALS OF ONCOLOGY, 2007, 18 (04) : 745 - 751
  • [22] Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients
    Janmaat, ML
    Gallegos-Ruiz, MI
    Rodriguez, JA
    Meijer, GA
    Vervenne, WL
    Richel, DJ
    Van Groeningen, C
    Giaccone, G
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (10) : 1612 - 1619
  • [23] Phase II study of docetaxel plus cisplatin as a second-line combined therapy in patients with advanced gastric carcinoma
    Kunisaki, C
    Imada, T
    Yamada, R
    Hatori, S
    Ono, H
    Otsuka, Y
    Matsuda, G
    Nomura, M
    Akiyama, H
    Kubo, A
    Shimada, H
    ANTICANCER RESEARCH, 2005, 25 (04) : 2973 - 2977
  • [24] Phase I/II study of gemcitabine and exisulind as second-line therapy in patients with advanced non-small cell lung cancer
    Hoang, Tien
    Kim, KyungMann
    Merchant, Joseph
    Traynor, Anne M.
    McGovern, James
    Oettel, Kurt R.
    Sanchez, Fredrico A.
    Ahuja, Harish G.
    Hensing, Thomas A.
    Larson, Martha
    Schiller, Joan H.
    JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (03) : 218 - 225
  • [25] Second-line treatment with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer:: Results of a multicenter phase II trial
    Boeck, Stefan
    Weigang-Koehler, Karin
    Fuchs, Martin
    Kettner, Erika
    Quietzsch, Detlev
    Trojan, Joerg
    Stoetzer, Oliver
    Mueller, Eva
    Depenbrock, Henrik
    Heinemann, Volker
    ANNALS OF ONCOLOGY, 2006, 17 : 322 - 322
  • [26] Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study
    Georgoulias, V
    Kouroussis, C
    Agelidou, A
    Boukovinas, I
    Palamidas, P
    Stavrinidis, E
    Polyzos, A
    Syrigos, K
    Veslemes, M
    Toubis, M
    Ardavanis, A
    Tselepatiotis, E
    Vlachonikolis, I
    BRITISH JOURNAL OF CANCER, 2004, 91 (03) : 482 - 488
  • [27] Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study
    V Georgoulias
    C Kouroussis
    A Agelidou
    I Boukovinas
    P Palamidas
    E Stavrinidis
    A Polyzos
    K Syrigos
    M Veslemes
    M Toubis
    A Ardavanis
    E Tselepatiotis
    I Vlachonikolis
    British Journal of Cancer, 2004, 91 : 482 - 488
  • [28] Efficacy of Docetaxel and Oxaliplatin Regimen as a Second-Line Therapy for Patients with Advanced Pancreatic Adenocarcinoma
    Amal Rayan
    Ola N. Abdel Fattah
    Ahmed Soliman
    Hosam A. Hasan
    Asmaa M. Zahran
    Journal of Gastrointestinal Cancer, 2019, 50 : 519 - 524
  • [29] Efficacy of Docetaxel and Oxaliplatin Regimen as a Second-Line Therapy for Patients with Advanced Pancreatic Adenocarcinoma
    Rayan, Amal
    Fattah, Ola N. Abdel
    Soliman, Ahmed
    Hasan, Hosam A.
    Zahran, Asmaa M.
    JOURNAL OF GASTROINTESTINAL CANCER, 2019, 50 (03) : 519 - 524
  • [30] Phase II study of gefitinib and docetaxel as salvage therapy in patients (pts) with advanced pancreatic adenocarcinoma (APC).
    Shadad, F.
    Matin, K.
    Evans, T. L.
    Volkin, R. L.
    Kiefer, G. J.
    Schlesselman, J. J.
    Cai, C.
    Schmotzer, A.
    Dranko, S.
    Ramanathan, R. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 207S - 207S
12345